NEW DELHI, June 11 — Scientists at the University of Cambridge have unveiled an artificial intelligence-driven vaccine platform designed to provide protection against entire families of viruses, a breakthrough that researchers say could help prevent future pandemics before they emerge.
For decades, global health systems have largely responded to outbreaks after new pathogens appear, developing vaccines only after viruses begin spreading among humans. Because viruses continually mutate, many vaccines, including those for seasonal influenza and COVID-19, require frequent updates to remain effective.
The new approach seeks to change that model by creating vaccines capable of protecting against a broad range of virus variants, including strains that have not yet emerged in humans.
To develop a universal coronavirus vaccine, researchers analyzed all available genetic sequence data for Sarbeco coronaviruses — the group that includes SARS-CoV-2 and SARS-related viruses. Using machine-learning technology, they designed a “super antigen” containing genetic features shared across the virus family, including potential future variants.
The findings were published in the peer-reviewed Journal of Infection, the official publication of the British Infection Association.
Researchers describe the strategy as “proactive vaccinology,” a method that aims to train the immune system to recognize and respond to a wide spectrum of viruses rather than targeting a single known pathogen.
The Cambridge-led team said the technology could provide broad protection against thousands of virus variants, including coronaviruses and Ebola-related viruses, through a single vaccine platform.
“We’ve converted vaccine development from being reactive to being future proof. Our vaccines will continue to provide protection against viruses even as they mutate into new strains,” said Jonathan Heeney of the University of Cambridge’s Department of Veterinary Medicine, who led the scientific research.
“We’ve overcome the problem of traditional vaccines, which have limited protection. It means we can escape the constant cycle of chasing the virus variants circulating in humans and updating the vaccines to try to catch up, like a dog chasing its tail,” he added.
The first human clinical trial of the universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and its spin-out company DIOSynVax (DVX) Ltd., demonstrated that the vaccine was safe and produced no significant side effects.
The study involved 39 healthy volunteers between the ages of 18 and 50 and evaluated a vaccine designed to protect against multiple Sarbeco coronaviruses.
According to researchers, the vaccine generated immune responses not only against SARS-CoV-2 and SARS but also against related bat coronaviruses that could potentially cross into human populations and trigger future outbreaks.
The technology uses AI-designed nanoparticle scaffolds that function as platforms displaying proteins from multiple viruses simultaneously. Unlike conventional vaccines that typically present the immune system with a single viral protein, the new platform allows scientists to combine proteins from various viruses into one vaccine.
Researchers used a specialized molecular binding technique to attach multiple viral antigens to the nanoparticle structure, enabling the immune system to identify common characteristics shared by an entire virus family.
They compared the approach to building a fortress prepared for many different types of intruders rather than a single known threat.
Laboratory testing showed that the vaccine generated “cross-reactive” immunity, meaning it triggered protective immune responses not only against viruses included in the vaccine but also against related viruses that were not part of the formulation.
Scientists believe this broad protection could provide a safeguard against “Disease X,” the term used to describe an unknown future pathogen capable of causing a global pandemic.
By moving beyond the traditional “one bug, one drug” model, researchers envision a future in which vaccines can be developed and stockpiled before dangerous viruses make the jump from animals to humans.
“Nature is constantly rolling the dice, waiting for the next mutation to jump from animals to humans,” the researchers noted. “For the first time, we aren’t just waiting to see what the dice reveal. We are changing the rules of the game.”
The clinical trials were conducted at the National Institute for Health and Care Research Clinical Research Facilities in Southampton and Cambridge and were sponsored by University Hospital Southampton NHS Foundation Trust. (ANI)
About The Author
